Bladder-sparing management for high grade noninvasive urothelial carcinoma of the prostate
In a high-risk cohort of patients with NMIUC-P, a select number of patients were able to avoid cystectomy and remain recurrence-free at 3-years after pursuing bladder-sparing intravesical treatment. However, given the high incidence of disease progression, careful patient selection is critical. Further prospective studies are needed to identify markers of response.
Authors
- Ryan L. Steinberg (ORCID: https://orcid.org/0000-0003-3558-0183)
- Alexander C. Martin (ORCID: https://orcid.org/0000-0002-8592-7838)
- Michael A. O’Donnell (ORCID: https://orcid.org/0000-0001-7202-6427)
- Sarah L. Mott (ORCID: https://orcid.org/0000-0001-9381-2080)
- Ian M. McElree (ORCID: https://orcid.org/0000-0001-9991-4301)
- Helen Y. Hougen (ORCID: https://orcid.org/0000-0003-3141-6474)
- Vignesh T. Packiam (ORCID: https://orcid.org/0000-0001-8397-7797)
Institutions
- Rutgers, The State University of New Jersey (US)
- University of Iowa (US)
Publication Details
- Journal
- Urologic Oncology Seminars and Original Investigations
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1016/j.urolonc.2025.04.007
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01